Zydus Lifesciences Ltd

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd held its 31st Annual General Meeting on August 11, 2026, through video conferencing, with the Chairman, Pankaj R. Patel, welcoming attendees and introducing the board members and key managerial personnel. The meeting was conducted in accordance with the Companies Act, 2013, and the circulars issued by MCA and SEBI. The company also announced the appointment of Kulin S. Lalbhai as an additional independent director, subject to shareholder approval.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd announced positive topline results from its completed EVIDENCES-X Phase II(b) clinical trial of Saroglitazar Mg in MASH, achieving its primary endpoint of resolution of steatohepatitis with no worsening of fibrosis.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has incorporated a wholly owned subsidiary, Zydus Global Treasury Centre IFSC Ltd, in Gift City, Gandhinagar, Gujarat.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has been assigned an ESG score of 66 by CRISIL, up from 61, indicating a 'strong' rating.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has made a disclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015, regarding the transmission of 32,577 equity shares from Late Jasodaben Babubhai Patel, a member of the promoter group, to Mr. Prashant Babubhai Patel.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has released an investor presentation for an upcoming investor conference, scheduled between August 24, 2026, to August 26, 2026.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has received an overall ESG rating of 60 from ESG Risk Assessments and Insights Limited, a SEBI registered ESG rating provider. The rating was prepared independently by ESGRAIL based on publicly available information. This disclosure is made in compliance with the provisions of regulation 30 of the Listing Regulations read with the SEBI Circulars.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has received final approval from the USFDA for its Abbreviated New Drug Application (ANDA) for Ascorbic Acid Injection, a generic equivalent of Ascor Injection, with 180-Days CGT exclusivity.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd reported Q1 FY27 results with consolidated revenues of ₹ 80.2 billion, up 22% YoY, and EBITDA margin of 24.1%. The company's net debt to EBITDA ratio stood at 0.7 times as on 30th June, 2026.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd will hold a Non-Deal Roadshow (NDR) in Singapore and Hong Kong from August 24-26, 2026, to meet investors.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has rescheduled its participation in the Motilal Oswal 22nd Annual Global Investor Conference from August 18 to August 17, 2026.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has published unaudited financial results for the quarter ended June 30, 2026, showing total income from operations of INR 80,170 million and net profit for the period after tax and non-controlling interest of INR 9,398 million.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has announced the voting results of its 31st Annual General Meeting (AGM) held on August 11, 2026. The meeting was conducted through video conferencing, and the voting results were disclosed in accordance with Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resolutions related to the adoption of audited standalone and consolidated financial statements, declaration of final dividend, and re-appointment of a director.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has informed that the shareholders have passed resolutions for the re-appointment of Dr. Sharvil P. Patel as Managing Director for a further period of five years and the appointment of Mr. Kulin S. Lalbhai as an Independent Director for a term of five years.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has announced the results of the remote e-voting and e-voting during its 31st Annual General Meeting (AGM), with all 9 resolutions passed with requisite majority.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd held its 31st Annual General Meeting (AGM) on August 11, 2026, through video conferencing. The meeting was attended by 106 members, including bodies corporate through their representatives. The Chairman, Pankaj R. Patel, briefed the members on the company's business performance, financial highlights, and major developments during the financial year ended March 31, 2026. The meeting was conducted in a fair and transparent manner, with remote e-voting and e-voting processes in place.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has made an announcement under Regulation 30 (LODR) regarding the outcome of an analyst/investor meet. The company has made available the audio recording of the investor call discussing unaudited financial results for the quarter ended June 30, 2026, on its website.

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd has reported a violation of the Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015, by one of its Designated Persons, Mr. Ashutosh Patil, who inadvertently traded in equity shares of the Company. The Company has issued a warning letter to Mr. Patil and collected an amount of Rs. 18,797/- as profit gained from the transaction.

Zydus Lifesciences Ltd

Zydus Lifesciences' subsidiary Sentynl Therapeutics has entered into an option and license agreement with Mereo BioPharma for the US commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD).

Zydus Lifesciences Ltd

Zydus Lifesciences Ltd reported Q1 FY27 financial results, with revenue from operations at Rs. 80,170 mn, up 22% y-o-y, and EBITDA at Rs. 19,294 mn, down 8% y-o-y. Net profit was Rs. 9,398 mn, down 36% y-o-y. The company's branded portfolio now exceeds 55% of revenues, with a strong presence in the US market.